base metals investing Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
base metals investing Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
base metals investing Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
base metals investing Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting
base metals investing Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
base metals investing Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635
base metals investing Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
base metals investing Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
